alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Plasma and spinal-fluid biomarkers

1,573 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Location-specific Longitudinal Patterns of Subcortical and Lobar Cerebral Microhemorrhages in Preclinical Alzheimer Disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-10-13 Genetics

    Emerging evidence and expert opinion suggest that subcortical microhaemorrhages may be less closely related to cerebral amyloidosis than lobar lesions and may therefore warrant separate consideration in anti-amyloid treatment eligibility criteria.

  2. Continuous amyloid staging complements global amyloid burden in early Alzheimer’s disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-10-11 Brain scans and imaging

    A continuous amyloid staging score complements global amyloid burden for early AD staging and cognitive risk stratification.

  3. α-Synuclein Seeding Activity in Fixed Antemortem Skin Biopsies From Patients With Synucleinopathies

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-11 Brain tissue and pathology

    Seeding readouts correlated with Hoehn and Yahr stage but not significantly with MoCA score or pS129 α-synuclein burden.

  4. Locus coeruleus intensity as a marker of early-stage Alzheimer’s disease: associations with plasma pTau 217 and memory

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-10-09 Genetics

    These findings support MRI-derived LC intensity as a marker of early AD-related processes and suggest that LC intensity may provide complementary information not captured by plasma pTau 217 alone.

  5. Analytical performance of a delayed-centrifugation blood collection tube for remote blood biomarker assessment

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-10-07 Biomarkers

    Current biobanking guidelines require in-person blood collection and immediate processing for Alzheimer’s disease (AD) biomarker assessment.

  6. Generalizing Amyloid β Pathology from Postmortem Human Brains with Vision Foundation Models for Lesion Quantification

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-10-07 Vascular contributions

    The ViTamyloid classifier achieved strong feature-separation metrics, yielding area under the receiver operating characteristic curve (AUROC) and precision-recall curve (AUPRC) values of 0.994/0.958 for CCP, 0.989/0.945 for CGP, 0.992/0.977 for CAA Type 1, and 0.997/0.978 for CAA Type 2.

  7. Blood Biomarkers of Alzheimer’s Disease Neuropathology, Cognition, and Response to a Multidomain Lifestyle Intervention: Secondary analysis of the FINGER Randomized Controlled Dementia Risk Reduction Trial

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-10-06 Biomarkers

    Interventions targeting lifestyle and health behaviors support cognition in older adults at risk of dementia.

  8. When Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantitation and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-10-06 Brain scans and imaging

    : Treated patients were 74±7 years old; 57% were female, 59% were apolipoprotein E ε4 carriers, and 78% had mild cognitive impairment (22% mild dementia).

  9. Large-scale cerebrospinal fluid proteomics identifies diagnostic biomarker candidates across the clinico-pathological continuum of frontotemporal lobar degeneration

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-10-05 Tau biomarkers

    Frontotemporal lobar degeneration (FTLD), predominantly comprised of tau and TDP-43 proteinopathies, is a common cause of early-onset dementia.

  10. Plasma eMTBR-tau as a robust biomarker for Alzheimer’s disease tangle pathology up to 10 years before death

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-10-05 Brain tissue and pathology

    Scalable and accessible biomarkers of neurofibrillary tangle pathology are needed for Alzheimer’s disease prognosis, diagnosis and monitoring.

  11. Decoding Dementia from Sweat: A Proof-of-Concept Label-Free Raman Fingerprinting of EVs

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-10-01 Lewy body dementia

    Dementia is a major global health challenge; however, current diagnostic approaches often rely on invasive or costly procedures.

  12. Tau-PET subtype modifies the association between plasma p-tau217 and memory in Alzheimer’s disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-09-28 Biomarkers

    Tau-PET subtype modified the p-tau217–memory association, suggesting that the cognitive implications of plasma p-tau217 may vary with tau topography.

  13. AT(N)-Anchored Multimodal Deep Learning for Alzheimer’s Staging: A Taxonomy and Continuous Burden Index for Low-Resource Settings

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2026-09-25 Tau biomarkers

    The global burden of dementia is heavily concentrated in low- and middle-income countries (LMICs), yet biological diagnosis of Alzheimer’s Disease (AD) relies on positron emission tomography (PET) and cerebrospinal fluid (CSF) analysis that are operationally inaccessible in these regions.

  14. White Matter Slow-4 fALFF as a Complementary Marker in the Multimodal Alzheimer’s Disease Biomarker Landscape

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-09-24 Biomarkers

    WM fALFF was significantly associated with GFAP (partial RZ = 5.35%), amyloid PET (partial RZ = 2.17%), tau PET (partial RZ = 3.52%), executive function (partial RZ = 2.61%), and mPACC (partial RZ = 3.53%).

  15. A Review of Alzheimer’s Pathophysiology, Diagnostic Methods, and Multimodal Techniques

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2026-09-24 Disease mechanisms

    Alzheimer's disease (AD) is a neurologic condition that is categorized by a progressive loss of neurons with time.

  16. Underlying histopathology features of white matter hyperintensities in vascular and neurodegenerative disorders: a systematic review

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-20 Lewy body dementia

    White matter hyperintensities (WMHs) are a hallmark of cerebral small vessel disease, commonly seen in cognitively normal older adults and patients with neurodegenerative disorders, and are thought to reflect varying degrees of tissue damage.

  17. Distinguishing Parkinsonian Disorders and Cognitive Disorder Subtypes Using Pseudocontinuous Arterial Spin Labeling

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2026-09-16 Lewy body dementia

    Arterial spin labelling (ASL) MRI provides a noninvasive measure of cerebral perfusion, raising the possibility of distinguishing Parkinson's disease (PD) from atypical parkinsonian syndromes (corticobasal syndrome, multiple system atrophy, progressive supranuclear palsy) and of separating the associated cognitive disorders, PD dementia and dementia with Lewy bodies (DLB), from Alzheimer's disease (AD).

  18. Quantitative Modelling of Amyloid-β Dynamics in Brain, CSF, and Plasma During Sleep and Wakefulness

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-09-14 Tau biomarkers

    Amyloid-beta (Aβ) accumulation in the brain is linked to Alzheimer’s disease.

  19. Tissue- and compartment-resolved brain age reveals vascular-metabolic and neurodegenerative aging

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-11 Long-term cohort studies

    Brain aging reflects heterogeneous vascular-metabolic and neurodegenerative processes, yet brain age is often reduced to a gray matter (GM)-dominant estimate.

  20. Amplitude of physiological brain pulsations in Alzheimer’s disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-10 Tau biomarkers

    Physiological pulsations maintaining brain neurofluidic homeostasis are altered early in the course of Alzheimer’s disease (AD).

  21. MRI-derived periventricular diffusivity contextualizes plasma pTau217 associations with Alzheimer pathology: a discovery–validation study

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-10 Brain scans and imaging

    PVeD reproducibly contextualized associations between plasma pTau217 and PET-defined Alzheimer pathology across cohorts with different participant composition, pTau217 assays, PET tracers, and cognitive measures.

  22. Plasma Fibrinogen Correlates with Aβ Clearance of monocytes and AD Biomarkers in Cognitively Normal Individuals

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-08 Biomarkers

    Impaired peripheral clearance of amyloid-β (Aβ) contributes to Alzheimer's disease (AD) pathogenesis.

  23. Does CSF testing add value after an indeterminate plasma p-tau217 result?

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-01 Biomarkers

    These data are compatible with, but do not establish, equivalence between plasma p-tau217 and CSF biomarkers.

  24. Five Decades of Infusion Testing in Idiopathic Normal Pressure Hydrocephalus: A Biomarker in Search of a Gold Standard

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Preprints.org 2026-09-01 Digital health tools

    Idiopathic normal pressure hydrocephalus (iNPH) is a potentially reversible cause of gait impairment, cognitive decline, and urinary dysfunction in older adults, yet identifying patients most likely to benefit from cerebrospinal fluid (CSF) diversion remains a major diagnostic challenge.

  25. Clinical expression beyond measured Alzheimer disease molecular pathology: a discovery and external evaluation study

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-08-31 Brain scans and imaging

    A prespecified structure–reserve–glial profile captured reproducible cognitive variation beyond measured Alzheimer disease molecular pathology across two cohorts.

From across this topic

10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

Other topics